92224-44-7 Usage
Uses
Used in Pharmaceutical Industry:
2,3,6,7-tetrahydro-1H-cyclopenta[d]pyridazine-1,4(5H)-dione is used as an antiepileptic agent for its potential to treat epilepsy by reducing seizure activity.
2,3,6,7-tetrahydro-1H-cyclopenta[d]pyridazine-1,4(5H)-dione is used as an analgesic agent for its potential to alleviate pain by modulating neurotransmitter release.
2,3,6,7-tetrahydro-1H-cyclopenta[d]pyridazine-1,4(5H)-dione is used as a psychiatric treatment for its potential to alleviate symptoms of depression and anxiety by modulating neurotransmitter release.
2,3,6,7-tetrahydro-1H-cyclopenta[d]pyridazine-1,4(5H)-dione is used as a neuroprotective agent for its potential to protect neurons and treat neurodegenerative diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 92224-44-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,2,2,2 and 4 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 92224-44:
(7*9)+(6*2)+(5*2)+(4*2)+(3*4)+(2*4)+(1*4)=117
117 % 10 = 7
So 92224-44-7 is a valid CAS Registry Number.
92224-44-7Relevant academic research and scientific papers
TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
-
Page/Page column 57, (2011/02/26)
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i
Organic Compounds as Smo Inhibitors
-
Page/Page column 42, (2010/03/04)
The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.
